Etrasimod Performs Well in Phase Phase 2b Trial of Adult Atopic Dermatitis
Nearly one-third of participants in the 2 mg etrasimod group achieved clear or almost clear skin, as defined by the validated Investigator Global Assessment (vIGA), the FDA endpoint for Phase 3 registration, according to topline results from Arena’s Phase 2b ADVISE clinical trial evaluating etrasimod for the moderate-to-severe atopic dermatitis (AD).